BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26621170)

  • 1. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
    Azanza JR; Sádada B; Reis J
    Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lipid formulations of amphotericin B.
    Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
    Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
    Bellmann R; Egger P; Wiedermann CJ
    Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparative review of conventional and lipid formulations of amphotericin B.
    Robinson RF; Nahata MC
    J Clin Pharm Ther; 1999 Aug; 24(4):249-57. PubMed ID: 10475983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based formulations of amphotericin B.
    Veerareddy PR; Vobalaboina V
    Drugs Today (Barc); 2004 Feb; 40(2):133-45. PubMed ID: 15045035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amphotericin B. Lipid complex versus liposomes. Which, why, when?].
    Pahissa A
    Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):1-3. PubMed ID: 9147499
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between liposomal formulations of amphotericin B.
    Adler-Moore JP; Gangneux JP; Pappas PG
    Med Mycol; 2016 Mar; 54(3):223-31. PubMed ID: 26768369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid formulations of amphotericin B.
    Jones E; Goldman M
    Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
    Groll AH; Müller FM; Piscitelli SC; Walsh TJ
    Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New methods for delivery of antifungal agents.
    Meunier F
    Rev Infect Dis; 1989; 11 Suppl 7():S1605-12. PubMed ID: 2690298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudohyperphosphatemia associated with high-dose liposomal and lipid complex amphotericin B when tested with Synchron LX 20 (Beckman/Coulter) phosphorous assay.
    Shiu JR; Forgie SE; Pinsk M; Romanick M
    J Pediatr Hematol Oncol; 2012 May; 34(4):e155-7. PubMed ID: 22146534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
    Bellmann R; Cleary JD; Sterba J
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
    Steimbach LM; Tonin FS; Virtuoso S; Borba HH; Sanches AC; Wiens A; Fernandez-Llimós F; Pontarolo R
    Mycoses; 2017 Mar; 60(3):146-154. PubMed ID: 27878878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal amphotericin B: clinical experience and perspectives.
    Gibbs WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.